Corporate News
Co‑Diagnostics Inc. (CODX) Market Update – Wednesday, 21 Nov 2026
Stock Performance
CODX closed 2.85 % lower at 06:03 PM CET.
Current trading price is USD 0.65.
24‑hour trading volume equals USD 366 000.
Market capitalisation stands at USD 5.1 million.
7.5 million shares are outstanding.
Since the end of the previous month, the share price has fallen 35.94 %.
200‑day simple moving average: USD 2.39.
52‑week high: USD 46.50 (27 Oct 2025).
52‑week low: USD 0.61 (20 Oct 2026).
Strategic Development
Co‑Diagnostics has announced that its joint venture, CoMira Diagnostics, has been invited by the Saudi Ministry of Industry and Mineral Resources to participate in the NUWATIN 2026 Forum.
The forum, scheduled for November, will convene senior government officials and industry leaders to discuss strategic manufacturing, technology transfer, and localization initiatives under Saudi Vision 2030.
CoMira aims to use the forum to strengthen relations with government and industry stakeholders and to advance its objective of establishing molecular diagnostics manufacturing in the Kingdom.
The company highlighted the recent lease of a manufacturing facility in Sudair Industrial City, which will support the localisation of its proprietary PCR platform.
The joint venture aligns with Saudi Arabia’s goal to develop domestic healthcare manufacturing capabilities and diversify the national economy.
Peer Activity (last 24 hours)
| Ticker | Price | % Move | Market Cap |
|---|---|---|---|
| AUUD | USD 0.98 | –7.82 % | USD 5.9 m |
| TRAW | USD 0.37 | +2.70 % | USD 5.6 m |
| GETY | USD 0.02 | +42.86 % | USD 5.7 m |
| PCSA | USD 1.74 | +3.47 % | USD 5.8 m |
| ACXP | USD 1.15 | 0 % | USD 6.0 m |
TRAW: The board has filed a definitive proxy statement for a special meeting on 3 Dec 2026. Items on the agenda include a reverse stock split (1‑for‑8 to 1‑for‑15) and the possibility of adjournment. Shareholders will vote electronically or via other approved methods. Results will be reported in a Form 8‑K within four business days.
GETY: The company has entered a pre‑packaged Chapter 11 bankruptcy to implement a financial restructuring that includes an equity infusion of up to USD 533 million from Getty family affiliates and Koch Equity Development. The filing includes a 30‑day grace period following a missed interest payment.
PCSA: No significant corporate action reported.
ACXP: No significant corporate action reported.
Company Overview Co‑Diagnostics Inc. specializes in the development, manufacturing, and sale of reagents for nucleic‑acid‑based diagnostic tests. The company also markets diagnostic equipment from other manufacturers as self‑contained laboratory systems. Products are sold globally. Public trading began on the Nasdaq exchange on 12 July 2017. More information can be found at www.codiagnostics.com .